Robert Lewandowski shoots down Barcelona exit question
Barcelona star Robert Lewandowski has offered a blunt response to rumours he could leave the club this summer.
Lewandowski enjoyed his best-ever campaign in Catalonia as the 36-year-old moved onto 101 goals in 147 appearances across three seasons.
Advertisement
2024/25 featured his strongest single-campaign tallies, with 27 scored in La Liga and 42 overall, as he narrowly missed out to Kylian Mbappe in the Golden Boot race.
Despite his ruthlessness in front of goal, rumours over his long-term future remain, as he prepares to turn 37 in August.
Lewandowski confirms Barcelona decision for 2025/26
As Lewandowski heads off on his summer break, the veteran striker told an interview with German outlet Bild that he has no intention of leaving, with his full focus on Barcelona.
'I've won more than 30 titles in my career. But I'm ready for more,' he said.
Image via Alex Grimm / Getty Images
'It's not an issue for me. I'll stay next season. Right now, all I have on my mind is Barcelona. Our team will be even better next season.'
Advertisement
Lewandowski's current Barcelona contract runs until June 2026, but both parties could take up the option to extend for another 12 months, if his performance level is maintained.
Barcelona's summer plan for Lewandowski
Barcelona will keep a close eye on Lewandowski during the off-season as they look to ensure he returns for preseason in top condition.
The No.9 has already pulled out of Poland's squad for their June games due to exhaustion from his domestic campaign.
'Due to the circumstances and the intensity of the club season, the coach and I have jointly decided I will not participate in the Polish national team's training camp in June.'
That call has drawn some criticism from within Poland, with one of the two games a 2026 World Cup qualifier against Finland, as he starts one of the longest breaks of his career with 7-8 unoccupied weeks on the horizon.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Matthäus believes Kimmich will beat his Germany caps record
Germany's Joshua Kimmich speaks during the press conference of the German national soccer team, ahead of Wednesday's UEFA Nations League semi-final soccer match against Portugal. Federico Gambarini/dpa Lothar Matthäus believes Joshua Kimmich has the potential to break his Germany caps record. Matthäus racked up 150 appearances for West Germany/Germany and Kimmich, 30, will pick up his 100th cap in the Nations League semi-final against Portugal in Munich on Wednesday. Advertisement "I said years ago, if anyone can catch up with me, it's Joshua. And I stand by that. He's still young, rarely injured and very ambitious. If he keeps going like this, he can reach 170 international caps," Matthäus told the Bild newspaper on Tuesday. The 1990 World Cup winner also wrote in a column for Sky: "I would be happy for him if he eventually breaks my record of 150 appearances." Kimmich has mainly operated at right back for Germany coach Julian Nagelsmann despite playing for Bayern Munich in midfield. Matthäus would like to see him in the centre of the park for Germany again. Advertisement "Kimmich is world-class as a right back and in midfield. I think he's most effective in the middle, where he dictates the rhythm of the game. As a right back, he's not as involved in the build-up," the 64-year-old said. "But Julian Nagelsmann doesn't have another player who fits the requirements for the right back position. I don't see another convincing solution there either."
Yahoo
35 minutes ago
- Yahoo
New Madeleine McCann search under way
Portuguese and German authorities have started a new search into the disappearance of Madeleine McCann in Portugal nearly two decades ago. Madeleine was three years old when she vanished from an apartment complex in the town Praia da Luz in Algarve during a family holiday on 3 May 2007. Her disappearance sparked a Europe-wide police investigation, and has become one of the highest-profile unsolved missing person cases in the world. On Monday, Portuguese police confirmed they were carrying out the search on warrants issued by German prosecutors. Portuguese police say the search - which covers the municipality of Lagos near Praia da Luz - is due to continue until Friday. Four vehicles carrying German police have arrived on the search site, the roads to which have been closed off. German investigators have taken the lead in the case since they identified Christian Brückner as their prime suspect in 2020. The 48-year-old is currently serving a sentence in Germany for a separate crime - the rape of a 72-year-old American tourist in Portugal in 2005. He is due to be released later this year. German authorities suspect him of murder but have not found enough evidence to bring charges, while Brückner repeatedly denies any involvement. Portuguese authorities have also named Brückner as a formal suspect, or "arguido". They said they would hand over any evidence seized in the latest search to German authorities. The team of German and Portuguese investigators have been given permission to search 21 plots of land between the Ocean Club resort Madeleine disappeared from and where Brückner had been staying at the time. German authorities told the BBC on Monday that "criminal proceedings are currently under way in Portugal" with the support of Portuguese police. The previous search was two years ago, focussed around a reservoir where Madeleine was last seen. Brückner, who spent time in the area between 2000 and 2017, was found to have photographs and videos of himself near the reservoir. The night Madeleine disappeared, her parents had been at dinner with friends at a restaurant a short walk away while Madeleine and her younger twin siblings were asleep in the ground-floor apartment. Her mother, Kate, discovered her was missing at around 22:00. A German documentary in 2022 found evidence that Brückner occasionally worked at the Ocean Club as a handyman, while German prosecutors have also linked his mobile phone data and a car sale to their case against him. Madeleine's parents last month marked the 18th year anniversary of her disappearance, saying their "determination to leave no stone unturned is unwavering". The Metropolitan Police - which this week said it was "aware of the searches being carried by the BKA (German federal police) in Portugal" - continues its investigation into Madeleine's disappearance. The case, known as Operation Grange, has been going since 2011.
Medscape
35 minutes ago
- Medscape
Relacorilant + Nab-Paclitaxel Beneficial in Ovarian Cancer
Relacorilant, a selective glucocorticoid receptor antagonist, combined with nab-paclitaxel significantly improved progression-free survival in women with platinum-resistant ovarian cancer. The interim analysis also showed meaningful improvement in overall survival, with median survival extending from 11.50 to 15.97 months. METHODOLOGY: While platinum-based chemotherapy is initially effective, about 70% of patients experience disease relapse that becomes platinum-resistant. Relacorilant, a selective glucocorticoid receptor antagonist, has demonstrated synergy with paclitaxel in nonclinical tumor models. The combination with nab-paclitaxel was chosen for this study because it does not require corticosteroid coadministration. Researchers conducted a randomized, controlled, open-label, phase 3 trial (ROSELLA [GOG-3073/ENGOT-ov72]) at 117 hospitals and community oncology treatment centers across 14 countries in Australia, Europe, Latin America, North America, and South Korea. Participants included 381 patients aged 18 years or older with confirmed platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer; up to three previous lines of anticancer therapy; and measurable disease as per Response Evaluation Criteria in Solid Tumors (version 1.1). Analysis involved comparing relacorilant (150 mg orally the day before, of, and after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m2 intravenously on days 1, 8, and 15 of each 28-day cycle) with nab-paclitaxel monotherapy (100 mg/m2 on the same schedule). TAKEAWAY: Patients receiving relacorilant plus nab-paclitaxel showed improved progression-free survival compared with those receiving nab-paclitaxel monotherapy (hazard ratio [HR], 0.70; 95% CI, 0.54-0.91; median, 6.54 months vs 5.52 months; stratified log-rank P = .0076). = .0076). Interim analysis revealed improved overall survival with relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy (HR, 0.69; 95% CI, 0.52-0.92; median, 15.97 months vs 11.50 months; log-rank P = .0121). = .0121). Safety profiles were comparable between the groups when adjusted for nab-paclitaxel exposure, with no new safety signals observed. IN PRACTICE: 'Combined with the evidence from previous studies, our study supports relacorilant plus nab-paclitaxel as a potential new standard of care for patients with platinum-resistant ovarian cancer, without the need for biomarker selection. This study is the first positive clinical trial conducted with registrational intent for a selective glucocorticoid receptor antagonist in patients with cancer,' authors of the study wrote. SOURCE: Lead author Alexander B. Olawaiye, MD, of the University of Pittsburgh School of Medicine and UPMC Magee-Womens Hospital, both in Pittsburgh, presented the results of the study at American Society of Clinical Oncology (ASCO) 2025. A paper on the study was published online in The Lancet on June 2. LIMITATIONS: The open-label design and applicability to patients with more than three lines of anticancer therapy were noted as limitations. While the risk of bias in progression-free survival assessment was mitigated by using blinded independent central review and a dual primary endpoint of overall survival, the median duration of the follow-up for overall survival was less than the estimated median overall survival in the relacorilant combination group at interim analysis. DISCLOSURES: The study was funded by Corcept Therapeutics. The authors reported that adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 5.0), with relatedness determined by the investigators. The funding source supported trial conduct, patient enrollment, and drug supply. The analysis, interpretation, writing, and submission decisions were the responsibility of the authors.
